REPEAT reaffirms the benefits of retreatment with PEG IFN-α-2a

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1524, 2006-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection

Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 495, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Sunitinib benefits HRQOL more than IFN-α in renal cell carcinoma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 523, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A Randomised Controlled Trial of IFN-α, IL-2 and 5FU Versus IFN-α Alone in Metastatic Renal Cell Carcinoma (ISRCTN 46518965)*

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 51-53

Ashgate Publishing Ltd

Access to resources Recommend Favorite